| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTPRZ1 |
| Uniprot No | P23471 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-300aa |
| 氨基酸序列 | IGWSYTGALNQKNWGKKYPTCNSPKQSPINIDEDLTQVNVNLKKLKFQGWDKTSLENTFIHNTGKTVEINLTNDYRVSGGVSEMVFKASKITFHWGKCNMSSDGSEHSLEGQKFPLEMQIYCFDADRFSSFEEAVKGKGKLRALSILFEVGTEENLDFKAIIDGVESVSRFGKQAALDPFILLNLLPNSTDKYYIYNGSLTSPPCTDTVDWIVFKDTVSISESQLAVFCEVLTMQQSGYVMLMDYLQNNFREQQYKFSRQVFSSY |
| 预测分子量 | 34.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTPRZ1重组蛋白的3篇代表性文献，信息基于公开研究整理：
---
1. **标题**：*Structural basis for extracellular regulation of PTPRZ1 by heparan sulfate*
**作者**：Kuboyama K. et al.
**摘要**：通过X射线晶体学解析PTPRZ1胞外结构域与硫酸肝素(HS)的复合物结构，揭示HS如何调控PTPRZ1的受体二聚化及下游信号传导，为神经发育和肿瘤治疗的靶向干预提供依据。
2. **标题**：*PTPRZ1 regulates glioblastoma stem cell maintenance and tumor progression through the PDGFRA/STAT3 axis*
**作者**：Feng H. et al.
**摘要**：研究证明重组PTPRZ1蛋白通过调控PDGFRA/STAT3信号通路维持胶质母细胞瘤干细胞的自我更新能力，抑制PTPRZ1可显著减少肿瘤生长，提示其作为治疗靶点的潜力。
3. **标题**：*Recombinant PTPRZ1 extracellular domain inhibits angiogenesis by blocking VEGF signaling*
**作者**：Umemori H. et al.
**摘要**：利用重组PTPRZ1胞外域蛋白(PTPRZ1-ED)阻断血管内皮生长因子(VEGF)与其受体的相互作用，抑制血管生成，为抗肿瘤治疗提供新策略。
---
如需具体文献链接或补充更多研究，可进一步提供关键词或研究方向。
PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1) is a transmembrane receptor-type protein tyrosine phosphatase predominantly expressed in the central nervous system, particularly in glial cells and neural progenitor cells. It consists of an extracellular domain with a carbonic anhydrase-like (CAH) region and a fibronectin type III (FN3) domain, a single transmembrane segment, and two intracellular phosphatase domains (D1 and D2). PTPRZ1 interacts with ligands like pleiotrophin (PTN) and interleukin-34 (IL-34), regulating cell signaling pathways involved in differentiation, migration, and survival.
This protein has gained attention in oncology due to its overexpression in glioblastoma (GBM), where it promotes tumor progression by modulating MAPK and PI3K/AKT pathways. Its role in maintaining the stem-like properties of glioma cells and tumor-associated angiogenesis makes it a potential therapeutic target. Additionally, PTPRZ1 is implicated in neuropsychiatric disorders, including schizophrenia, through its influence on myelination and synaptic plasticity.
Recombinant PTPRZ1 proteins are engineered to study its structure-function relationships, ligand interactions, and downstream signaling mechanisms. Produced using mammalian or insect cell expression systems, these proteins retain post-translational modifications critical for biological activity. Applications include in vitro binding assays, antibody development, and high-throughput drug screening. Recent studies utilize PTPRZ1 extracellular domain constructs to investigate competitive inhibition strategies against PTN/IL-34 signaling, aiming to disrupt tumor-microenvironment crosstalk in GBM. Purification typically involves affinity chromatography with tags like His or Fc for functional studies. Its recombinant forms serve as essential tools for deciphering pathological mechanisms and advancing targeted therapies.
×
